ClinicalTrials.gg
CompletedNCT05084053Updated Jun 24, 2026Results posted

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

A Phase 3 interventional study of TAK-771 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN), sponsored by Takeda. Completed at 23 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan — 7 open to participants now, 9 under way, 8 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Japan.

Enrollment
15th of 16
26 · median 160
Started
2022
with 1 other
Phase 3
12 of 16
6 open now
Registered
8th of 16
by date
Lead sponsor
2 of 16
Takeda

Among the 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan, this one is the 15th largest by enrollment, is one of 2 that started in 2022, is one of 12 in phase 3, and was the 8th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

7 of the 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Japan, or all of them as a file.
02

Study summary

The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN)

The participants will be treated with TAK-771 for 45 months as a maximum.

There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 2, 3, or 4 weeks).

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Multifocal Motor Neuropathy (MMN)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a Japanese person.
  2. The participant is male or female >=18 years old at the time of screening.
  3. Participant has a documented diagnosis of definite or probable CIDP (focal atypical CIDP and pure sensory atypical CIDP will be excluded) or definite or probable MMN, as confirmed by a neurologist specializing/experienced in neuromuscular diseases to be consistent with the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) 2010 criteria.
  4. Participant has responded to IgG treatment in the past (partial or complete resolution of neurological symptoms and deficits), and must currently be on stable doses of IVIG treatment within the dose range equivalent to a cumulative monthly dose of 0.4 to 2.4 g/kg BW (inclusive) administered intravenously for at least 12 weeks prior to screening. The dosing interval of intravenous immunoglobulin (IVIG) treatment must be between 2 and 6 weeks (inclusive). Variations in the dosing interval of up to ±7 days or monthly dose amount of up to +or-20% between participant's pre-study IgG infusions are within acceptable limits.
  5. CIDP participants only - INCAT disability score between 0 and 7 (inclusive). Participants with INCAT scores of 0, 1 (whether from upper or lower extremities), or 2 (if at least 1 point is from an upper extremity) at screening and/or baseline will be required to have a history of significant disability as defined by an INCAT disability score of 2 (must be exclusively from the lower extremities) or greater documented in the medical record. Participants will be eligible if one of the below eligibility criteria are met:

    1. Screening and Baseline INCAT disability score between 3 and 7 inclusive.
    2. Screening and/or Baseline INCAT disability score of 2 (both points are from lower extremities)
    3. Screening and/or Baseline INCAT disability score of 2 (both points are not from lower extremities) AND has at least a score of 2 or greater documented in the medical record prior to screening. If a score was greater than 2 documented in the medical record prior to screening at least 2 points must be from lower extremities.
    4. Screening and/or Baseline INCAT disability score of 0 or 1 AND has at least a score of 2 or greater (both from lower extremities) documented in the medical record prior to screening, at least 2 points must be from lower extremities.
  6. If female of , the participant must have a negative pregnancy test at screening and agree to employ a highly effective measure throughout the course of the study and for at least 30 days after the last administration of IP.
  7. The participant is willing and able to sign an Form (ICF).
  8. The participant is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria CIDP patients

  1. Participants with focal atypical CIDP or pure sensory atypical CIDP or multifocal acquired demyelinating sensory and motor neuropathy (MADASAM).
  2. Participants with any neuropathy of other causes, including:

    1. Hereditary demyelinating neuropathies, such as hereditary sensory and motor neuropathy (HSMN) (Charcot-Marie-Tooth [CMT] disease), and hereditary sensory and autonomic neuropathies (HSANs).
    2. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy, lymphoma, and amyloidosis.
    3. Multifocal motor neuropathy (MMN).
    4. Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy. MMN patients
  3. Participant with other neuropathies (eg, diabetic, lead, porphyric or vasculitic neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, Lyme neuroborreliosis, post radiation neuropathy, hereditary neuropathy with liability to pressure palsies, CMT neuropathies, meningeal carcinomatosis).

    CIDP/MMN Patients

  4. Participant with immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with high titer antibodies to myelin-associated glycoprotein.
  5. Participant with presence of prominent sphincter disturbance.
  6. Participant with any central demyelinating disorders such as multiple sclerosis.
  7. Participant with any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of endpoint measures, including (but not limited to) arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy.

    (Participants with clinically diagnosed diabetes mellitus who do not have diabetic peripheral neuropathy and who have adequate glycemic control with [HbA1c] level of \<7.5% at screening will be eligible for the study, provided the electrodiagnostic criteria are consistent with the diagnosis of a definite or probable CIDP consistent with the EFNS/PNS 2010 criteria and the participant agrees to maintain adequate glycemic control.)

  8. Participant with congestive heart failure ( [NYHA] class III/IV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension (defined as diastolic blood pressure >100 mmHg and/or systolic blood pressure >160 mmHg).
  9. Participant with a history of deep vein thrombosis or thromboembolic events (eg, cerebrovascular accident, pulmonary embolism) within 12 months prior to screening.
  10. Participant with condition(s) which could alter protein catabolism and/or IgG utilization (eg, protein-losing enteropathies, nephrotic syndrome).
  11. Participant with a known history of chronic kidney disease, or of \<60 mL/min/1.73m\^2 estimated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at the time of screening.
  12. Participant with active requiring chemotherapy and/or radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions to this exclusion are: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment.
  13. Participant with anemia that precludes repeated blood sampling during the study, or (Hgb) level of \<10.0 g/dL at the time of screening.
  14. Participant with a known history of or ARs such as urticaria, breathing difficulty, severe hypotension, or anaphylaxis following administration of human blood products such as human IgG, albumin, or other blood components.

    (Clinically non-significant skin reactions, as per the investigator's and the sponsor medical monitor's discretion, do not meet this exclusion criterion. Clinically non-significant skin reactions may include local reactions to injection such as injection site's itching, redness, erythema, or swelling.)

  15. Participant has a known allergy to hyaluronidase of human (including recombinant human hyaluronidase) or animal origin such as bee or wasp venom.
  16. Participant with immunoglobulin A (IgA) deficiency and antibodies against IgA and a history of hypersensitivity.
  17. Participant with an abnormal laboratory values at screening meeting any one of the following criteria:

    1. Serum (AST) and alanine aminotransferase (ALT) >2.5 x (ULN).
    2. count \<100,000 cells/microL.
    3. (ANC) \<1000 cells/microL.
  18. Participant has a known history of or is positive at screening for one or more of the following: surface antigen (HBsAG), polymerase chain reaction (PCR) for virus (HCV), PCR for (HIV) Type 1/2.
  19. Participant has received or is currently receiving treatment with immunomodulatory/ agents within 6 months prior to screening.
  20. Participant has received or is currently receiving treatment with any dose within 8 weeks prior to screening, regardless of indication.
  21. Participant has undergone PE within 3 months prior to screening.
  22. Participant has any disorder or condition that in the investigator's judgment may impede the participant's participation in the study, pose increased risk to the participant, or confound the results of the study.
  23. Participant is nursing or intends to begin nursing during the course of the study.
  24. Participant has participated in another clinical study involving an IP or device within 30 days prior to enrollment, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
  25. Participant is a family member or employee of the investigator.
  26. Participants with known acquired or inherited thrombophilic disorders. These will include the specific types of acquired or inherited thrombophilic disorders that could put participants at risk of developing thrombotic events. Examples include a. Hereditary thrombophilia: i. Factor V Leiden mutation. ii. Prothrombin 20210A mutation. iii. Protein C deficiency. iv. Protein S deficiency. v. Anti-thrombin deficiency. b. Acquired thrombophilia: i. Anti-phospholipid antibody syndrome. ii. Activated protein C Resistance acquired. iii. Homocystinemia.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Cohort 1: TAK-771 for CIDP Participants

    TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.

    Drug: TAK-771

  • Experimental
    Cohort 2: TAK-771 for MMN Participants

    TAK-771 includes IGI 10% and rHuPH20. Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.

    Drug: TAK-771

Interventions

  • Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

    Also known as: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

06

What researchers measure

Primary outcomes

  1. Epoch 1: Percentage of Participants With CIDP Who Experienced Relapse

    Relapse was defined as worsening of functional disability defined as an increase of \>=1 point relative to the pre-subcutaneous (pre-SC) treatment baseline score in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. The INCAT disability scale was the most widely used assessment tool to measure the functional activity level of participants with CIDP. The INCAT disability scale consisted of upper and lower extremity components, with a maximum of 5 points for the upper extremities (arm disability) and a maximum of 5 points for the lower extremities (leg disability), which were summed for an overall INCAT disability score ranging from 0 to 10 points, where 0 was normal and 10 was severely incapacitated. An adjusted INCAT disability score was the same as the INCAT disability score, with the only exception in the exclusion of changes from 0 (normal) to 1 (minor symptoms) (or vice versa) in upper limb function.

    Time frame: Epoch 1: Baseline up to 6 months

  2. Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN

    The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kilopascal (kPa) ranging from 0 to 160 kPa.

    Time frame: Epoch 1: Baseline up to 6 months

Secondary outcomes

  1. Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as adverse events that occurred during or after administration of the first dose of investigational product (IP). TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months).

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  2. Epoch 1 and 2 (6 Months): Number of Participants With Serious Adverse Events (SAEs)

    SAEs were defined as any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: resulted in death, was life-threatening, required inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, or any other important medical event.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  3. Epoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs

    Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  4. Epoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious Adverse Reactions (ARs) Plus Suspected ARs

    Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  5. Epoch 1 and 2 (6 Months): Number of Participants With SAEs and/or TEAEs Associated With Infusions

    Infusion associated SAEs and/or TEAEs were defined as SAEs and/or TEAEs considered to be "infusion-related reactions" by investigators.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  6. Epoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs Associated With Infusions

    Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible. SAEs and TEAEs associated with infusions were the events considered to be "infusion-related reactions" by investigators.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  7. Epoch 1 and 2 (6 Months): Number of Participants With TEAEs Temporally Associated With Infusions

    TEAEs were defined as adverse events that occurred during or after administration of the first dose of IP. TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months). TEAEs temporally associated with infusions defined as AEs occurring during or within 72 hours after completion of an infusion.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  8. Epoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious ARs Plus Suspected ARs Temporally Associated With Infusions

    Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion. AEs temporally associated with infusions are defined as AEs occurring during or within 72 hours after completion of an infusion.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  9. Epoch 1 and 2 (6 Months): Number of Participants With Systemic TEAEs Associated With Infusions

    Any TEAEs other than local TEAEs were considered a systemic TEAE. Infusion associated TEAEs were defined as TEAE considered to be "infusion-related reactions" by investigators.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  10. Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions

    Any reaction with the medical dictionary for regulatory activities (MedDRA) high-level group term (HLGT) of "Administration site reactions" were considered a local infusion site reaction (local TEAE). In addition, any TEAE with Injection Site Reaction Flag = "Yes" was considered a local TEAE. Infusion associated reaction were defined as event considered to be "infusion-related reactions" by investigators.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  11. Epoch 1 and 2 (6 Months): Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Intolerability and/or AEs

    Number of infusions for which the infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs were reported.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  12. Epoch 1 and 2 (6 Months): Number of Participants With Positive Binding Antibodies, and Positive Neutralizing Antibodies to rHuPH20

    Plasma samples for the detection of anti-rHuPH20 binding and neutralizing antibodies were collected. Participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the Screening and Confirmatory Binding Assay). Positive antibodies were defined as participants who had anti rHuPH20 antibody titer greater than or equal to (\>=) 1:160 at least one time during treatment.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  13. Epoch 1: Percentage of Participants With Clinical Worsening of CIDP

    Clinical Worsening of CIDP was defined as a \>=8 kPa decrease in hand grip strength in the more affected hand OR \>=4 points decrease in Rasch Built Overall Disability Scale (R-ODS) relative to the pre-SC treatment baseline score at 2 consecutive time points. Hand grip strength was measured using the Martin vigorimeter by quantifying air pressure. The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.

    Time frame: Epoch 1: Baseline until end of Epoch 1 or relapse (up to 6 months)

  14. Epoch 1 and 2 (6 Months): Time to Relapse in Participants With CIDP

    Time to relapse was defined as time from the date of the first SC administration of TAK-771 in Epoch 1 or 2 to the date of relapse.

    Time frame: Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1

  15. Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in R-ODS Total Score in Participants With CIDP

    The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.

    Time frame: Epoch 1: Baseline up to 6 months

  16. Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in an Average of Handgrip Strength of Both Hands in Participants With CIDP and MMN

    The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kPa ranging from 0 to 160 kPa. Average of grip strength was defined as an average of the two maximum values: maximum of the 3 measurements in the more affected hand and the maximum of the 3 measurements in the less affected hand.

    Time frame: Epoch 1: Baseline up to 6 months

  17. Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) Total Medical Research Council (MRC) Sum Score in Participants With MMN

    The MRC sum score served as a measure of muscle strength. The following muscles on each side of the body were examined and the strength of each muscle was rated according to the MRC scale: deltoids, biceps, wrist extensors, iliopsoas, quadriceps, and anterior tibialis. The MRC scale ranged from 0 to 5, where: 0 = no visible contraction; 1 = visible contraction without movement of the limb; 2 = movement of the limb but not against gravity; 3 = movement against gravity over (almost) the full range; 4 = movement against gravity and resistance; and 5 = normal. All scores from both left and right side of the body were summed to obtain the total MRC sum score. The total MRC sum score ranged from 0 (paralysis) to 60 (normal strength) with higher score indication normal strength.

    Time frame: Epoch 1: Baseline up to 6 months

  18. Epoch 1: Number of MMN Participants With Increased Guy's Neurological Disability Scale (GNDS) Score in Upper Limb and Lower Limb Categories

    GNDS was a questionnaire which consisted of 12 separate categories (4 to 8 questions per category). The categories included: cognition, mood, vision, speech, swallowing, upper limb function, lower limb function, bladder function, bowel function, sexual function, fatigue, and others. In the current study, only 2 categories; upper limb function and the lower limb function was used for assessment of the disability of participants with MMN. The severity of each subscale (including upper limb and lower limb) was graded from 0 (normal function) to 5 (total loss of function) based according to severity and impact on the individual. The total GNDS score was the sum of the 12 separate scores ranging between 0 and 60 with higher scores indicating loss of function.

    Time frame: Epoch 1: Baseline up to 6 months

07

Results

Posted Mar 18, 2025

Participant flow

Participants took part in the study at 23 investigative sites in Japan. A total of 26 participants were enrolled and treated in this study, which consisted of two treatment epochs (Epoch 1 and Epoch 2) with two cohorts: chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Cohort 1 and multifocal motor neuropathy (MMN) in Cohort 2.

Epoch 1: Up to 6 Months
Participant flow — Epoch 1: Up to 6 Months
MilestoneEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Started19700
Treated19700
Completed17700
Not completed2000
Withdrew: Withdrawal by subject1000
Withdrew: Physician decision1000
Epoch 2: Up to 6 Months
Participant flow — Epoch 2: Up to 6 Months
MilestoneEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Started00167
Treated00167
Completed00157
Not completed0010
Withdrew: Physician decision0010

Outcome measures

PrimaryEpoch 1: Percentage of Participants With CIDP Who Experienced Relapse

Relapse was defined as worsening of functional disability defined as an increase of \>=1 point relative to the pre-subcutaneous (pre-SC) treatment baseline score in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. The INCAT disability scale was the most widely used assessment tool to measure the functional activity level of participants with CIDP. The INCAT disability scale consisted of upper and lower extremity components, with a maximum of 5 points for the upper extremities (arm disability) and a maximum of 5 points for the lower extremities (leg disability), which were summed for an overall INCAT disability score ranging from 0 to 10 points, where 0 was normal and 10 was severely incapacitated. An adjusted INCAT disability score was the same as the INCAT disability score, with the only exception in the exclusion of changes from 0 (normal) to 1 (minor symptoms) (or vice versa) in upper limb function.

Time frame:
Epoch 1: Baseline up to 6 months
Reported as:
Number · percentage of participants
Epoch 1: Percentage of Participants With CIDP Who Experienced Relapse
percentage of participantsEpoch 1, Cohort 1 (CIDP): TAK-771
Epoch 1: Percentage of Participants With CIDP Who Experienced Relapse0 (0.00 to 17.65)
PrimaryEpoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN

The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kilopascal (kPa) ranging from 0 to 160 kPa.

Time frame:
Epoch 1: Baseline up to 6 months
Reported as:
Mean · kPa
Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN
kPaEpoch 1, Cohort 2 (MMN): TAK-771
Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMN-1.1 ± 12.73
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as adverse events that occurred during or after administration of the first dose of investigational product (IP). TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months).

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs)167116
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Serious Adverse Events (SAEs)

SAEs were defined as any untoward clinical manifestation of signs, symptoms, outcomes (related to IP or not) at any dose: resulted in death, was life-threatening, required inpatient/prolongation of hospitalization, resulted in persistent/significant disability/incapacity, congenital abnormality/birth defect, or any other important medical event.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Serious Adverse Events (SAEs)
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Epoch 1 and 2 (6 Months): Number of Participants With Serious Adverse Events (SAEs)0000
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs

Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Participants With Related SAEs0000
Participants With Related TEAEs11574
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious Adverse Reactions (ARs) Plus Suspected ARs

Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious Adverse Reactions (ARs) Plus Suspected ARs
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Participants with Serious ARs Plus Suspected ARs0000
Participants with non-serious ARs Plus Suspected ARs12674
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With SAEs and/or TEAEs Associated With Infusions

Infusion associated SAEs and/or TEAEs were defined as SAEs and/or TEAEs considered to be "infusion-related reactions" by investigators.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With SAEs and/or TEAEs Associated With Infusions
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Participants with SAEs associated with Infusions0000
Participants with TEAEs associated with Infusions9564
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs Associated With Infusions

Related SAES and TEAEs: that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications and concurrent treatments, may also be responsible. SAEs and TEAEs associated with infusions were the events considered to be "infusion-related reactions" by investigators.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Related SAEs and TEAEs Associated With Infusions
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Participants With Related SAEs Associated With Infusions0000
Participants With Related TEAEs Associated With Infusions9564
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With TEAEs Temporally Associated With Infusions

TEAEs were defined as adverse events that occurred during or after administration of the first dose of IP. TEAEs caused in Epoch 1 were defined as AEs that occurred on or after the start of study drug administration, and before the first dose of IP in Epoch 2 (6 months). TEAEs caused in Epoch 2 (6 months) were defined as AEs that began during or after administration of the first dose of IP in Epoch 2 (6 months). TEAEs temporally associated with infusions defined as AEs occurring during or within 72 hours after completion of an infusion.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With TEAEs Temporally Associated With Infusions
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Epoch 1 and 2 (6 Months): Number of Participants With TEAEs Temporally Associated With Infusions12674
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious ARs Plus Suspected ARs Temporally Associated With Infusions

Adverse reactions plus suspected ARs were defined as TEAEs that were considered by the investigator to be related to IP administration, or for which the causality was indeterminate or missing, or that began during infusion of IP or within 72 hours following the end of IP infusion. AEs temporally associated with infusions are defined as AEs occurring during or within 72 hours after completion of an infusion.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Serious and Non-serious ARs Plus Suspected ARs Temporally Associated With Infusions
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Participants with Serious ARs Plus Suspected ARs Temporally Associated with Infusions0000
Participants with Non-serious ARs Plus Suspected ARs Temporally Associated with Infusions12674
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Systemic TEAEs Associated With Infusions

Any TEAEs other than local TEAEs were considered a systemic TEAE. Infusion associated TEAEs were defined as TEAE considered to be "infusion-related reactions" by investigators.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Systemic TEAEs Associated With Infusions
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Epoch 1 and 2 (6 Months): Number of Participants With Systemic TEAEs Associated With Infusions3432
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions

Any reaction with the medical dictionary for regulatory activities (MedDRA) high-level group term (HLGT) of "Administration site reactions" were considered a local infusion site reaction (local TEAE). In addition, any TEAE with Injection Site Reaction Flag = "Yes" was considered a local TEAE. Infusion associated reaction were defined as event considered to be "infusion-related reactions" by investigators.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Epoch 1 and 2 (6 Months): Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions9554
SecondaryEpoch 1 and 2 (6 Months): Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Intolerability and/or AEs

Number of infusions for which the infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs were reported.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Number · infusions
Epoch 1 and 2 (6 Months): Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Intolerability and/or AEs
infusionsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Epoch 1 and 2 (6 Months): Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Intolerability and/or AEs2001
SecondaryEpoch 1 and 2 (6 Months): Number of Participants With Positive Binding Antibodies, and Positive Neutralizing Antibodies to rHuPH20

Plasma samples for the detection of anti-rHuPH20 binding and neutralizing antibodies were collected. Participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the Screening and Confirmatory Binding Assay). Positive antibodies were defined as participants who had anti rHuPH20 antibody titer greater than or equal to (\>=) 1:160 at least one time during treatment.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Count of participants · Participants
Epoch 1 and 2 (6 Months): Number of Participants With Positive Binding Antibodies, and Positive Neutralizing Antibodies to rHuPH20
ParticipantsEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Participants with Positive Antibodies2232
Participants with Positive Neutralizing Antibodies0000
SecondaryEpoch 1: Percentage of Participants With Clinical Worsening of CIDP

Clinical Worsening of CIDP was defined as a \>=8 kPa decrease in hand grip strength in the more affected hand OR \>=4 points decrease in Rasch Built Overall Disability Scale (R-ODS) relative to the pre-SC treatment baseline score at 2 consecutive time points. Hand grip strength was measured using the Martin vigorimeter by quantifying air pressure. The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.

Time frame:
Epoch 1: Baseline until end of Epoch 1 or relapse (up to 6 months)
Reported as:
Number · percentage of participants
Epoch 1: Percentage of Participants With Clinical Worsening of CIDP
percentage of participantsEpoch 1, Cohort 1 (CIDP): TAK-771
Epoch 1: Percentage of Participants With Clinical Worsening of CIDP21.1 (8.51 to 43.33)
SecondaryEpoch 1 and 2 (6 Months): Time to Relapse in Participants With CIDP

Time to relapse was defined as time from the date of the first SC administration of TAK-771 in Epoch 1 or 2 to the date of relapse.

Time frame:
Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1
Reported as:
Median · weeks
Epoch 1 and 2 (6 Months): Time to Relapse in Participants With CIDP
weeksEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771
Epoch 1 and 2 (6 Months): Time to Relapse in Participants With CIDPNA (NA to NA)NA (NA to NA)
SecondaryEpoch 1: Change From Pre-subcutaneous Treatment (Baseline) in R-ODS Total Score in Participants With CIDP

The R-ODS was a participant self-reported, linearly-weighted overall disability scale that was specifically designed to capture activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. R-ODS was comprised of 24 items that rate participant's functioning related to a variety of everyday tasks at moment of completion on a scale of 0 to 2 (where 0 indicates it is not possible for the respondent to perform the task and 2 means that task can be performed without difficulty). Total scores range from 0 to 48 and higher scores indicate greater ability to perform daily and social tasks.

Time frame:
Epoch 1: Baseline up to 6 months
Reported as:
Mean · score on scale
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in R-ODS Total Score in Participants With CIDP
score on scaleEpoch 1, Cohort 1 (CIDP): TAK-771
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in R-ODS Total Score in Participants With CIDP0.1 ± 3.24
SecondaryEpoch 1: Change From Pre-subcutaneous Treatment (Baseline) in an Average of Handgrip Strength of Both Hands in Participants With CIDP and MMN

The Martin Vigorimeter was used to assess grip strength in both hands. The instrument consisted of a compressible rubber ball that was connected to a manometer. When the rubber ball was squeezed, the force of compression was measured in kPa ranging from 0 to 160 kPa. Average of grip strength was defined as an average of the two maximum values: maximum of the 3 measurements in the more affected hand and the maximum of the 3 measurements in the less affected hand.

Time frame:
Epoch 1: Baseline up to 6 months
Reported as:
Mean · kPa
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in an Average of Handgrip Strength of Both Hands in Participants With CIDP and MMN
kPaEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) in an Average of Handgrip Strength of Both Hands in Participants With CIDP and MMN4.03 ± 9.749-0.36 ± 10.613
SecondaryEpoch 1: Change From Pre-subcutaneous Treatment (Baseline) Total Medical Research Council (MRC) Sum Score in Participants With MMN

The MRC sum score served as a measure of muscle strength. The following muscles on each side of the body were examined and the strength of each muscle was rated according to the MRC scale: deltoids, biceps, wrist extensors, iliopsoas, quadriceps, and anterior tibialis. The MRC scale ranged from 0 to 5, where: 0 = no visible contraction; 1 = visible contraction without movement of the limb; 2 = movement of the limb but not against gravity; 3 = movement against gravity over (almost) the full range; 4 = movement against gravity and resistance; and 5 = normal. All scores from both left and right side of the body were summed to obtain the total MRC sum score. The total MRC sum score ranged from 0 (paralysis) to 60 (normal strength) with higher score indication normal strength.

Time frame:
Epoch 1: Baseline up to 6 months
Reported as:
Mean · score on scale
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) Total Medical Research Council (MRC) Sum Score in Participants With MMN
score on scaleEpoch 1, Cohort 2 (MMN): TAK-771
Epoch 1: Change From Pre-subcutaneous Treatment (Baseline) Total Medical Research Council (MRC) Sum Score in Participants With MMN-0.3 ± 3.59
SecondaryEpoch 1: Number of MMN Participants With Increased Guy's Neurological Disability Scale (GNDS) Score in Upper Limb and Lower Limb Categories

GNDS was a questionnaire which consisted of 12 separate categories (4 to 8 questions per category). The categories included: cognition, mood, vision, speech, swallowing, upper limb function, lower limb function, bladder function, bowel function, sexual function, fatigue, and others. In the current study, only 2 categories; upper limb function and the lower limb function was used for assessment of the disability of participants with MMN. The severity of each subscale (including upper limb and lower limb) was graded from 0 (normal function) to 5 (total loss of function) based according to severity and impact on the individual. The total GNDS score was the sum of the 12 separate scores ranging between 0 and 60 with higher scores indicating loss of function.

Time frame:
Epoch 1: Baseline up to 6 months
Reported as:
Count of participants · Participants
Epoch 1: Number of MMN Participants With Increased Guy's Neurological Disability Scale (GNDS) Score in Upper Limb and Lower Limb Categories
ParticipantsEpoch 1, Cohort 2 (MMN): TAK-771
Participants with increased GNDS score in Upper Limb1 (1.25 to —)
Participants with Increased GNDS Score in Lower Limb0 (1.57 to —)

Adverse events

Collected over Epoch 1: Baseline up to 6 months; Epoch 2: Up to 6 months post-Epoch 1. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoch 1, Cohort 1 (CIDP): TAK-7710/19 (0%)0/19 (0%)16/19 (84.2%)
Epoch 1, Cohort 2 (MMN): TAK-7710/7 (0%)0/7 (0%)7/7 (100%)
Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-7710/16 (0%)0/16 (0%)11/16 (68.8%)
Epoch 2 (6 Months), Cohort 2 (MMN): TAK-7710/7 (0%)0/7 (0%)6/7 (85.7%)
Most frequent other events
Showing 10 of 67
Most frequent other events
EventEpoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Epoch 2 (6 Months), Cohort 1 (CIDP): TAK-771Epoch 2 (6 Months), Cohort 2 (MMN): TAK-771
Injection site erythemaGeneral disorders8/192/74/160/7
Administration site painGeneral disorders2/191/71/162/7
Infusion site erythemaGeneral disorders0/191/70/162/7
NasopharyngitisInfections and infestations2/192/73/160/7
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/190/70/162/7
SinusitisInfections and infestations0/192/70/160/7
HeadacheNervous system disorders4/191/74/160/7
Injection site pruritusGeneral disorders3/190/71/160/7
PruritusSkin and subcutaneous tissue disorders3/190/72/161/7
Abdominal distensionGastrointestinal disorders0/191/70/161/7

Baseline characteristics

Full Analysis Set (FAS) included all enrolled participants who received TAK-771 at least once.

Age, Continuous
Age, Continuous(years)Epoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Total
Mean54.9 ± 17.2757.4 ± 15.7155.6 ± 16.59
Sex: Female, Male
Sex: Female, Male(Participants)Epoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Total
Female8210
Male11516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Epoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Total
Hispanic or Latino000
Not Hispanic or Latino19726
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Epoch 1, Cohort 1 (CIDP): TAK-771Epoch 1, Cohort 2 (MMN): TAK-771Total
American Indian or Alaska Native000
Asian19726
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

23 sites
  • Aichi Medical University Hospital
    Nagakute, Aichi-ken, Japan
  • Chubu Rosai Hospital
    Nagoya, Aichi-ken, Japan
  • Fujita Health University Hospital
    Toyoake, Aichi-ken, Japan
  • Asahikawa Medical Center
    Asahikawa, Hokkaido, Japan
  • Kansai Rosai Hospital
    Amagasaki, Hyōgo, Japan
  • Hyogo College of Medicine Hospital
    Nishinomiya, Hyōgo, Japan
  • St.Marianna University School of Medicine Hospital
    Kawasaki, Kanagawa, Japan
  • Tohoku Medical and Pharmaceutical University Hospital
    Sendai, Miyagi, Japan
  • Nara Medical University Hospital
    Kashihara, Nara, Japan
  • Shiga University of Medical Science Hospital
    Ōtsu, Shiga, Japan
  • Tokushima National Hospital
    Yoshinogawa, Tokushima, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo, Japan
  • National Center of Neurology and Psychiatry
    Kodaira, Tokyo, Japan
  • Toho University Omori Medical Center
    Ōta-ku, Tokyo, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo, Japan
  • Yamaguchi University Hospital
    Ube, Yamaguchi, Japan
  • Chiba University Hospital
    Chiba, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Hiroshima University Hospital
    Hiroshima, Japan
  • Kumamoto University Hospital
    Kumamoto, Japan
  • Higashimatsuyama Municipal Hospital
    Saitama, Japan
  • Tokushima University Hospital
    Tokushima, Japan
  • Toyama University Hospital
    Toyama, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Oct 2025, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2021
First posted
Oct 19, 2021
StartActual
Jan 19, 2022
Primary completionActual
Oct 28, 2025
CompletionActual
May 29, 2026
Results first posted
Mar 18, 2025
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05084053
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Jan 19, 2022
Primary completion
Oct 28, 2025
Completion
May 29, 2026
Results posted
Mar 18, 2025
Last update
Jun 24, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion